U.S. Markets close in 4 hrs 8 mins

NeuroBo Pharmaceuticals, Inc. (NRBO)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
5.18-0.42 (-7.50%)
As of 11:35AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.60
Open5.42
Bid5.13 x 2200
Ask5.23 x 3000
Day's Range5.13 - 5.42
52 Week Range5.13 - 30.00
Volume8,385
Avg. Volume28,476
Market Cap85.534M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateAug 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.00
  • NeuroBo Pharmaceuticals Appoints Douglas J. Swirsky to the Board of Directors
    PR Newswire

    NeuroBo Pharmaceuticals Appoints Douglas J. Swirsky to the Board of Directors

    NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced that Douglas J. Swirsky, President and Chief Executive Officer of publicly traded Rexahn Pharmaceuticals, Inc., has been appointed to the Company's Board of Directors, effective September 1, 2020. In addition to his position as an independent director, Mr. Swirsky will also serve as a member of the Audit Committee. He replaces Steven Gullans, Ph.D., who resigned from the Board of Directors effective August 31, 2020.

  • NeuroBo Pharmaceuticals Reports Second Quarter 2020 Financial Results
    PR Newswire

    NeuroBo Pharmaceuticals Reports Second Quarter 2020 Financial Results

    NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced financial results for the second quarter ended June 30, 2020.

  • NeuroBo Pharmaceuticals to Join Russell 3000® and Microcap® Indexes
    PR Newswire

    NeuroBo Pharmaceuticals to Join Russell 3000® and Microcap® Indexes

    NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today reported that the company is scheduled to join the broad-market Russell 3000® and Microcap® Indexes at the conclusion of the 2020 Russell indexes annual reconstitution, effective after the US market opens on June 29, according to a final list of additions posted June 15.